Sensei Biotherapeutics (NASDAQ:FTH) Trading 5.3% Higher – Time to Buy?

Sensei Biotherapeutics, Inc. (NASDAQ:FTH)’s stock price rose 5.3% during mid-day trading on Monday . The company traded as high as $33.39 and last traded at $33.6850. 57,815 shares traded hands during trading, a decline of 72% from the average daily volume of 209,544 shares. The stock had previously closed at $32.00.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on FTH shares. Weiss Ratings assumed coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. Needham & Company LLC began coverage on Sensei Biotherapeutics in a research report on Friday. They set a “buy” rating and a $56.00 target price on the stock. Citigroup assumed coverage on shares of Sensei Biotherapeutics in a report on Friday, May 22nd. They issued a “buy” rating and a $55.00 price target on the stock. Wall Street Zen raised shares of Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Oppenheimer started coverage on shares of Sensei Biotherapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Sensei Biotherapeutics has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Sensei Biotherapeutics Price Performance

The business has a fifty day simple moving average of $27.27. The stock has a market capitalization of $881.58 million, a PE ratio of -0.24 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.04) by $2.20. Equities analysts forecast that Sensei Biotherapeutics, Inc. will post -13.18 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Brian C. Stephenson purchased 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was purchased at an average cost of $23.50 per share, with a total value of $117,500.00. Following the completion of the acquisition, the chief financial officer directly owned 46,688 shares in the company, valued at $1,097,168. This trade represents a 11.99% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Anand Kiran Parikh purchased 2,806 shares of Sensei Biotherapeutics stock in a transaction dated Monday, June 22nd. The stock was acquired at an average cost of $19.76 per share, with a total value of $55,446.56. Following the completion of the acquisition, the chief executive officer directly owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have purchased 49,494 shares of company stock worth $1,188,822. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Sensei Biotherapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of FTH. Vivo Capital LLC purchased a new stake in shares of Sensei Biotherapeutics in the first quarter valued at $22,758,000. Alyeska Investment Group L.P. acquired a new position in Sensei Biotherapeutics in the second quarter valued at $3,610,000. Stempoint Capital LP purchased a new stake in Sensei Biotherapeutics during the first quarter valued at about $4,188,000. Bank of America Corp DE increased its stake in Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after purchasing an additional 20,525 shares during the period. 10.50% of the stock is owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.